

Volpara expands association with GE Healthcare

27 March 2019 | News | By Manbeena Chawla

GE Healthcare is now a global distributor of Volpara®Density™ software



Volpara Solutions, the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand, has announced the launch of an expanded agreement enabling the worldwide distribution of its industry-leading VolparaDensity software by GE Healthcare.

Now installed in more than 35 countries, the VolparaDensity clinical application analyses mammograms using machine learning to provide radiologists with automated, objective, and volumetric breast density assessments and a breast density category shown to correlate to BI-RADS 4th and 5th Editions.

With more than 100 peer-reviewed papers and more than 250 publications, VolparaDensity is the most clinically validated breast density assessment software in the world. It is CE-marked and cleared by the FDA, Health Canada, and the TGA.

Having an objective and validated measure of breast density allows providers to deliver personalized breast care to their patients by easily identifying women with dense breasts. Such women have an increased risk of developing breast cancer and are also at a greater risk of having a cancer go undetected using conventional 2D and 3D mammography. Since dense breast tissue and cancer appear white on a mammogram, women with dense breasts may benefit from additional screening such as that delivered by the GE Invenia® Automated Breast Ultrasound (ABUS). ABUS has been shown to find small, invasive cancers missed by mammography.